Takeda Pharmaceutical Company Limited 보도자료

8월 8일 15:25

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cT...

8월 1일 14:00

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Takeda (TOKYO:4502/NYSE:TAK ) today announced earnings results for the first quarter of fiscal year 2024 (period ended June 30, 2024), with continued momentum in its Growth & Launch Products driving Core growth at CER and more than offsetting reve...

8월 1일 14:00

다케다, 2024 회계연도 1분기 실적 발표… 성장 및 출시 제품에 의한 강력한 실적, 유망한 후기 단계 파이프라인의 발전

다케다(Takeda)(TOKYO:4502/NYSE:TAK )가 7월 31일(현지 시간) 성장 및 출시 제품의 지속적인 모멘텀이 일정환율(Constant Exchange Rate, CER) 기준으로 핵심 성장을 주도하고 이전 회계연도에 발생한 상당한 독점권 손실로 인한 매출 영향을 상쇄하고도 남는 2024 ...

6월 27일 14:20

Takeda Announces New Assignments of Directors

Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Ta...

6월 27일 14:20

다케다, 새로운 이사 임명 발표

다케다(Takeda)(TOKYO:4502/NYSE:TAK)가 오사카에서 개최된 제148차 정기 주주총회에 이어 이사회 회의와 감사 및 감독 위원회 회의에서 결정된 새로운 이사 선임을 발표했다. 다케다 이사회는 총 14명 중 11명이 사외이사로 재직하고 있어 투명성과 객관성을 확보하...

6월 25일 09:26

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

Takeda (TSE:4502/NYSE:TAK ) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing ant...

6월 23일 13:54

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Takeda (TSE:4502/NYSE:TAK ) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic pri...

6월 23일 12:47

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated...

6월 20일 14:15

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Takeda (TSE:4502/NYSE:TAK ) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] ...

6월 20일 14:15

다케다, PNS 연례회의서 만성 염증성 탈수초성 다발성 신경병증 환자 대상 ‘하이큐비아®’의 제3상 ADVANCE-CIDP 3 임상시험 장기 데이터 발표

다케다(Takeda)(TSE:4502/NYSE:TAK) 가 만성 염증성 탈수초성 다발성 신경병증(Chronic Inflammatory Demyelinating Polyneuropathy, CIDP) 환자를 대상으로 하이큐비아®(HYQVIA®)(재조합 인간 히알루로니다아제를 사용한 면역 글로불린 주입 10%(인간))의 안전성과 ...

6월 18일 09:05

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda (TSE:4502/NYSE:TAK ) today announced topline data from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 study that evaluated soticlestat (TAK-935) plus standard of care versus placeb...

6월 16일 10:00

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Takeda (TSE:4502/NYSE:TAK ) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhi...

6월 4일 08:57

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

Takeda (TSE: 4502/NYSE:TAK ) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and...

6월 2일 14:57

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

Takeda (TSE:4502/NYSE:TAK ) and Pfizer (NYSE: PFE ) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as...

6월 2일 13:33

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE:4502/NYSE:TAK ) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for the...

5월 15일 10:30

Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting

Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill. ...

5월 14일 09:55

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

Takeda (TSE:4502/NYSE:TAK ) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the tre...

5월 13일 10:20

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performa...

5월 13일 10:20

다케다, FY2023 연간 실적 및 FY2024 전망 발표… 후기 단계 파이프라인 개발 및 핵심영업이익 마진 확대 위한 노력 확인

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK)가 FY2023(2024년 3월 31일 마감) 재무 실적을 오늘 발표하며, 독점권 상실의 영향이 컸던 해에 핵심영업이익에 대한 경영 지침을 달성하고 CER에서 매출 및 핵심 EPS 실적에 대한 경영 지침을 초과했다고 ...

4월 28일 13:10

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK ) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor ...

4월 9일 13:19

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food

Takeda (TSE:4502/NYSE:TAK ) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social Responsibility (CSR) program. To create greater i...

3월 28일 10:30

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Fur...